HSBC Holdings plc vs Smith & Nephew plc — how do they compare? HSBC Holdings plc trades at $100.64 (market cap $335.21B), while Smith & Nephew plc trades at $30.16 (market cap $12.64B). The key difference: HSBC Holdings plc is far larger — about 26.5× Smith & Nephew plc's market cap, and HSBC Holdings plc pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| HSBC | SNN | |
|---|---|---|
Market Cap | $335.21B | $12.64B |
Sector | Technology | Health |
52-Week High | $100.61 | $38.70 |
52-Week Low | $61.30 | $28.73 |
Dividend Yield | 3.79% | 2.57% |
Enterprise Value | — | $15.41B |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows strong technical momentum with bullish moving averages, though oscillators suggest potential overbought conditions. Fundamentally, the bank maintains robust profitability with 30.81% net income margin and 10.89% ROE, supported by recent earnings beats and a $0.50 dividend declaration. Recent news highlights strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a mixed outlook with solid fundamentals and strategic initiatives balanced against valuation concerns and regional risks. The bank's focus on AI integration and market exits could drive efficiency, but regulatory challenges and economic uncertainty pose headwinds. Analyst consensus leans cautious with 38% buy ratings, suggesting selective opportunity for long-term investors despite near-term overbought signals.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →